title: [Continuation of chemotherapy with bevacizumab for advanced and recurrent colorectal cancer].
abstract: We evaluated the association between the number of treatment courses with the concomitant use of bevacizumab(BV) and the reasons for discontinuation of the regimen in patients who received FOLFOX with or without BV as first-line chemotherapy and FOLFIRI with or without BV as second-line chemotherapy for advanced and recurrent colorectal cancer. In first-line treatment, 12 (2-46) and 10 (2-60) treatment courses were administered with and without BV, respectively, and this difference was not significant (p=0.60). In second-line treatment after first-line treatment with the concomitant use of BV, 11 (1-23) and 3 (1-12) treatment courses were administered with and without BV, respectively, and this difference was significant (p<0.01). Discontinuation due to adverse reactions was more frequent for first-line treatment (34.9%) than for second-line treatment (6.2%; p<0.01). The reasons for discontinuation due to adverse reactions during first-line treatment with BV were often associated with BV, and those during first-line treatment without BV were most often associated with peripheral neuropathy. Therefore, we conclude that early detection and prevention of adverse reactions are important in first-line treatment and that pharmacists as well should be involved in the monitoring and management of adverse reactions, although continued administration of BV even during second-line treatment after first-line treatment with BV is recommended.
authors.affiliation: Dept. of Pharmacy, Takatsuki General Hospital.
authors.forename: Yuko
authors.initials: Y
authors.lastname: Soga
authors.forename: Daisuke
authors.initials: D
authors.lastname: Ito
authors.forename: Hiroki
authors.initials: H
authors.lastname: Asano
authors.forename: Makiko
authors.initials: M
authors.lastname: Go
authors.forename: Mina
authors.initials: M
authors.lastname: Iwai
authors.forename: Kazutomo
authors.initials: K
authors.lastname: Okada
authors.forename: Tomoko
authors.initials: T
authors.lastname: Matsuoka
authors.forename: Sino
authors.initials: S
authors.lastname: Adachi
authors.forename: Eiseki
authors.initials: E
authors.lastname: Usami
authors.forename: Michio
authors.initials: M
authors.lastname: Kimura
authors.forename: Toshiya
authors.initials: T
authors.lastname: Nakao
authors.forename: Tomoaki
authors.initials: T
authors.lastname: Yoshimura
authors.forename: Tadashi
authors.initials: T
authors.lastname: Yasuda
authors.forename: Tomotaka
authors.initials: T
authors.lastname: Ogawa
authors.forename: Akifumi
authors.initials: A
authors.lastname: Iwaki
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D000068258:Bevacizumab; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012008:Recurrence
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab